phase readout
saveNCT05289687: Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
community read0 votes
Sponsor: Eastern Cooperative Oncology Group. Phase: PHASE2. Conditions: T-cell Acute Lymphoblastic Leukemia
view source ↗Data sources
last refreshed 5h ago
Found something off?
same company · ±60 days · 6
- earningsJOHNSON & JOHNSON earningsOct 13, 2026
- earningsJOHNSON & JOHNSON earningsJul 15, 2026
- approvalSTELARA (USTEKINUMAB) — FDA approvalApr 15, 2026
- device pmaJohnson & Johnson Surgical Vision, Inc. — TECNIS PureSee IOL, Model DEN00V TECNIS PureSee Toric II IOLs, Model DET150, DET225, DET300, DET375 (PMA supplement)Mar 11, 2026
- device pmaVistakon, Johnson & Johnson Vision Products, Inc. — VISTAKON® (etafilcon A) lenses (PMA supplement)Mar 10, 2026
- device pmaJohnson & Johnson Surgical Vision, Inc. — SENSAR 1-piece IOL, AAB00; SENSAR Soft Acrylic Posterior Chamber IOL, Models AR40e, AR40E, and AR40M; TECNIS 1-Piece I (PMA supplement)Jan 12, 2026
related news · 8
- biospaceBMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
- biospaceFoghorn cuts 40% of workforce
- biospace6 immunology targets to sustain a mammoth I&I market
- endpointsEndpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy
- biospaceJ&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
- fiercebiotechIndivior ends PAM drug collab with Addex ahead of Supernus merger
- biospaceThe human cost of AI interviews
- biospaceGrowth mode: 3 biotechs that are staffing up after series B raises
🐶 often sniffed alongside
top 7- tagOphthalmology26 co-mentions · 24 sources
- tagAdCom24 co-mentions · 24 sources
- tagPMA Approval24 co-mentions · 24 sources
- drugHYDROCODONE BITARTRATE AND ACETAMINOPHEN2 co-mentions · 1 sources
- tagRecall1 co-mentions · 1 sources
- drugOXYCODONE AND ACETAMINOPHEN1 co-mentions · 1 sources
- drugACETAMINOPHEN AND IBUPROFEN1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that